drugset / Trial / NCT00073970
Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy
Phase 2
Terminated
37 enrolled
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who have relapsed prostate cancer following radiation therapy or radical prostatectomy.
Timeline
- Start
- 2003-04
- Primary completion
- 2005-06
- Completion
- 2006-01
Outcome
Outcome not reported
Stopped: “Study stopped due to increased cardiovascular risks associated with Celebrex”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 400 mg | Oral |